{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:45:24Z","timestamp":1788432324260,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.intimp.2017.11.031","type":"journal-article","created":{"date-parts":[[2017,11,26]],"date-time":"2017-11-26T01:00:26Z","timestamp":1511658026000},"page":"303-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"special_numbering":"C","title":["Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0715-4523","authenticated-orcid":false,"given":"Zuzhen","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2017.11.031_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2500\/aap.2012.33.3569","article-title":"Epidemiology of atopic dermatitis: a review","volume":"33","author":"DaVeiga","year":"2012","journal-title":"Allergy Asthma Proc."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.031_bb0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ACI.0b013e3282ffd6cc","article-title":"Quality of life of children with atopic dermatitis and their families","volume":"8","author":"McKenna","year":"2008","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.031_bb0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2133.2003.05092.x","article-title":"Prevalence of atopic dermatitis in Japanese adults","volume":"148","author":"Muto","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.031_bb0020","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.031_bb0025","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"24","key":"10.1016\/j.intimp.2017.11.031_bb0030","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.031_bb0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2340\/00015555-0207","article-title":"Systemic treatment of severe atopic eczema: a systematic review","volume":"87","author":"Schmitt","year":"2007","journal-title":"Acta Derm. Venereol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.031_bb0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00128071-200607020-00005","article-title":"Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice","volume":"7","author":"Lubbe","year":"2006","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.031_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/11597780-000000000-00000","article-title":"Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis","volume":"13","author":"Frankel","year":"2012","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.031_bb0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2017.11.031_bb0055","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1468-3083.2012.04635.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) part I","volume":"26","author":"Ring","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.031_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10013","key":"10.1016\/j.intimp.2017.11.031_bb0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2017.11.031_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.intimp.2017.11.031_bb0075","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.031_bb0080","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2017.11.031_bb0085","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug evaluation review: dupilumab in atopic dermatitis","volume":"7","author":"Hamilton","year":"2015","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.intimp.2017.11.031_bb0090","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.11.031_bb0095","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.intimp.2017.11.031_bb0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12026-011-8205-2","article-title":"Transcriptional regulation by STAT6","volume":"50","author":"Goenka","year":"2011","journal-title":"Immunol. Res."},{"issue":"9","key":"10.1016\/j.intimp.2017.11.031_bb0105","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/jid.2008.74","article-title":"Th2 cytokines act on S100\/A11 to downregulate keratinocyte differentiation","volume":"128","author":"Howell","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.031_bb0110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin. Immunol. (Orlando, Fla)"},{"issue":"5","key":"10.1016\/j.intimp.2017.11.031_bb0115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous Dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"issue":"10086","key":"10.1016\/j.intimp.2017.11.031_bb0120","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2015","journal-title":"Lancet"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T20:43:50Z","timestamp":1538685830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576917304514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":24,"alternative-id":["S1567576917304514"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.031","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}